

# The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Mahran Shoukier, Gautam Borthakur, Elias Jabbour, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Jairo Matthews, Lucia Masarova, Kiran Naqvi, Koji Sasaki, Srdan Verstovsek and Jorge Cortes<sup>°</sup>

Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>°</sup>Current address: Georgia Cancer Center, Augusta University, Augusta, GA, USA

©2021 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2020.260125

Received: May 21, 2020.

Accepted: September 3, 2020.

Pre-published: September 14, 2020.

Correspondence: JORGE CORTES - [jorge.cortes@augusta.edu](mailto:jorge.cortes@augusta.edu)

---

N	Baseline PLT count x x10 <sup>9</sup> /L	Best PLT count x10 <sup>9</sup> /L	TKI line	TKI	TKI dose mg before eltrombopag	TKI at last follow - up	TKI dose mg at last follow - up	Duration of eltrombopag months	Response
1	34	210	2	dasatinib	50	dasatinib	100	77	CCyR
2	29	123	1	dasatinib	100	nilotinib	400	18	None
3	47	174	3	dasatinib	50	dasatinib	100	19	Partial
4	34	106	1	nilotinib	600	ponatinib	30	17	Partial
5	48	265	4	ponatinib	7.5	ponatinib	15	63	CCyR
6	49	248	4	ponatinib	7.5	ponatinib	7.5	17	None
7	48	133	3	bosutinib	300	bosutinib	300	62	Partial
8	44	424	5	bosutinib	300	bosutinib	300	12	Partial
9	49	227	3	dasatinib	50	dasatinib	100	51	CCyR
10	37	259	2	imatinib	400	dasatinib	100	48	CCyR
11	20	893	2	nilotinib	300	nilotinib	400	38	CCyR
12	19	163	1	ponatinib	15	ponatinib	15	8	None
13	42	93	1	dasatinib	70	dasatinib	70	5	None
14	39	1225	3	ponatinib	30	ponatinib	30	6	None
15	3	12	2	nilotinib	150	nilotinib	150	5	None

**Plt:** platelets; **TKI:** tyrosine kinase inhibitor.